For many in the pharmaceutical industry, their customer engagement solution has been based on Veeva iRep + Salesforce.com. However, the termination of Veeva Systems’ partnership with Salesforce holds significant implications for the pharma customer engagement landscape. As of September 2025, Veeva will be offering its own proprietary CRM solution to new installations; existing Veeva customers have until 2030 to transition from Salesforce to the Veeva CRM.

For companies that rely on Veeva to support their customer engagement, there are many implications to consider, risks to mitigate, and opportunities to explore. According to Animesh Ghandi, Gartner’s Life Sciences Industry Analyst, “It is crucial for life science CIOs to seize this opportunity and reevaluate their CRM solutions, ensuring they effectively enhance revenue, minimize costs, and foster customer engagement and satisfaction.” But what does this entail, and where do we start?

Join Pitcher and a select group of likeminded executives as we discuss the “divorce” between Veeva and Salesforce including your concerns, the risks involved, as well as the positive aspects and opportunities that lie ahead.

Pitcher provides the platform of choice for end-to-end sales enablement for pharmaceutical and other regulated industries, with customers in 140 countries. Customers rely on Pitcher’s omnichannel, end-to-end unified sales enablement platform to streamline selling, increase management visibility, deliver closed-loop marketing capabilities, and ensure full compliance regardless of communication channel. Pitcher customers achieve commercial excellence and significantly increased ROI. Based in Zürich, Switzerland and Denver, Colorado USA, Pitcher serves customers from offices in the US, Europe, and Asia.